In the phase III clinical trial, objective response rates in metastatic melanoma with BRAF mutations were 48% for vemurafenib and 5% for dacarbazine, the gold standard treatment for metastatic melanoma at that time, resulting in a significant difference in survival rates at six months (84% in the vemurafenib group vs. 64% in the dacarbazine group) [77]. This evidence concerns the gene BRAF and metastatic melanoma.